Smoking and menopause: earlier, worse, and riskier

It brings menopause forward

Smokers reach menopause on average one to two years earlier than non-smokers, and the effect is dose-dependent.

The mechanism is direct: polycyclic aromatic hydrocarbons in tobacco smoke are toxic to ovarian follicles and accelerate their depletion. Smoking also affects oestrogen metabolism, increasing its breakdown.

Earlier menopause is not simply an earlier inconvenience. It means more years of life at low oestrogen, and the associated increases in long-term bone and cardiovascular risk that accompany an early transition.

It makes the symptoms worse

Smoking is one of the few factors consistently associated with more frequent and more severe vasomotor symptoms, across multiple studies.

The relationship holds in a dose-dependent way, and former smokers generally have symptom rates closer to never-smokers than to current smokers, which suggests the effect is at least partly reversible.

This is worth stating because it is one of the few genuinely modifiable influences on hot flash frequency rather than on bother.

It accelerates bone loss

Smoking reduces bone density through several routes: direct effects on bone-forming cells, reduced calcium absorption, lower body weight on average, and the earlier menopause itself.

It appears in every major fracture risk assessment tool as an independent risk factor, which reflects how consistent the association is.

Stacked on top of the accelerated postmenopausal bone loss already occurring, this is the period when the combination does most damage.

It changes what can be prescribed

Smoking increases the risk of blood clots and cardiovascular events, and that interacts with hormone therapy decisions.

The route matters here: oral oestrogen passes through the liver and affects clotting factors, while transdermal oestrogen largely avoids this and is generally considered not to increase clot risk in the same way. For a smoker, that distinction becomes more relevant rather than less.

Combined hormonal contraception, which is different from hormone therapy, is generally avoided in smokers over 35 for the same reasons — a point that catches out women who are still using it in perimenopause.

When to see someone

Ask for stopping-smoking support, which is substantially more effective than willpower alone and is free in many health systems. Combining medication with behavioural support roughly triples success rates.

Mention smoking explicitly when discussing hormone therapy, since it affects which route is preferred. Ask for fracture risk assessment, since smoking raises it independently and is factored into the calculation.